NCT04725240View on ClinicalTrials.gov

Open-Label Study of Setmelanotide in Hypothalamic Obesity

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

June 28, 2022

Study Completion Date

June 28, 2022

Conditions
Hypothalamic Obesity
Interventions
DRUG

Setmelanotide

Setmelanotide for SC injection

Trial Locations (5)

37232

Vanderbilt University School of Medicine, Nashville

55102

Children's Minnesota, Saint Paul

92123

Rady Children's Hospital, San Diego

98101

Seattle Children's Research Institute, Seattle

32610-0296

University of Florida, Gainesville

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY